Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. EMEA/
      2. Our innovation /
      3. Focus areas/
      4. Oncology

      Oncology

      Johnson & Johnson is leading where medicine is going to transform outcomes for people living with cancer. With unwavering determination, we are committed to pioneering new ways to detect, intercept and treat this disease. We are constantly listening and learning from patients, caregivers and healthcare professionals we serve—every day they inspire us to advance the next wave of innovation and reshape care for tomorrow. Our aim is not only to take down cancer, but to strive towards cures. We aspire to get in front of cancer.

      Despite the incredible work of the oncology community across Europe, cancer remains the second leading cause of death in this region.[1][2] We fiercely believe that collaboration is essential to drive change and equitable innovation in cancer. Our dedicated teams are continually working with researchers, innovators, health authorities, governments and advocacy groups, who share our vision to make cancer a preventable and curable disease.[3][4] We strive for a future where hearing the words “you have cancer” will be less terrifying for patients, and less distressing for healthcare professionals to act upon.
      JJMTIM_Photo_PatientComfort_01_9256.jpg
      Our focus and leadership
      Bold and immediate action from the global health community is needed to propel oncology science forward. As the world’s largest pharmaceutical company with over three decades of expertise in cancer behind us, we combine our talent, capabilities and scale to drive the elimination of this disease. Our focus is in areas of the greatest unmet need, where we believe we can disrupt and meaningfully transform cancer care for patients, partners, and the entire oncology community.
      Oncology in numbers
      • Cancer remains the second leading cause of death worldwide. In 2022, there were an estimated 4 million new cases and 1.9 million deaths attributed to cancer in Europe.[5]
      • Over 50,000 people in Europe were newly diagnosed with multiple myeloma in 2022, while more than 31,900 patients died as a result of the disease.[6] Unmet needs also remain very high in lymphomas. Europe saw over 129,300 new cases of non-Hodgkin lymphoma recorded in 2022, the most common haematologic malignancy. [7]
      • The European region recorded the highest global rates of bladder cancer in both men and women in 2022.[8] In the same year, over 224,000 people were diagnosed and there were more than 70,300 deaths.[9] Investment into research for the disease has been lacking, compared to other cancers.[10]
      • More than 473,000 people were diagnosed with prostate cancer in 2022 in Europe, and over 115,000 people died as a result of the disease in that same timeframe.[11] It is the most commonly diagnosed cancer in European men. [12]
      • Lung cancer is the leading cause of global cancer incidence and mortality,[13] with over 484,300 European patients diagnosed in 2022.[12] In fact, Europe sees the second-highest number of lives lost to lung cancer worldwide.[8]
      Our oncology areas of focus
      Our commitment to pioneer new therapeutic advances in haematologic malignancies and solid tumours has never been stronger.
      Multiple myeloma
      We want to improve outcomes for patients with this rare, incurable blood cancer.
      June 6, 2024
      B-cell malignancies
      There are many different types of B cell malignancies.[14] We’re focused on four main types.
      June 6, 2024
      Prostate cancer
      We have over ten years’ experience in research in prostate cancer, the most common cancer among men in the EU.[12]
      June 6, 2024
      Bladder cancer
      Despite therapies being available, there is a high unmet need in bladder cancer due to poor outcomes. We are striving to change that.[15][16]
      June 6, 2024
      Lung cancer
      We’re concentrating on developing targeted therapies for patients with lung cancer, the leading cause of cancer death for men and women in Europe.[12]
      June 6, 2024

      References

      [1] WHO. Cancer Overview. 2024. https://www.who.int/health-topics/cancer#tab=tab_1. Accessed April 2025.
      [2] European Commission. Cancer. 2024. Available at: https://health.ec.europa.eu/non-communicable-diseases/cancer_en. Accessed April 2025.
      [3] Janssen.com/emea. Our Collaborations. Available at: https://www.janssen.com/emea/our-responsibility/our-collaborations. Accessed April 2025.
      [4] Janssen.com/emea. Industry, research and commercial collaborations. Available at: https://www.janssen.com/emea/our-responsibility/our-collaborations/industry-collabs. Accessed April 2025.
      [5] Globocan 2022. International Agency for Research on Cancer. Cancer Today. All Cancers. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/39-all-cancers-fact-sheet.pdf. Accessed April 2025.
      [6] Globocan 2022. International Agency for Research on Cancer. Cancer Today. Multiple Myeloma. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/35-multiple-myeloma-fact-sheet.pdf. Accessed April 2025.
      [7] Globocan 2022. International Agency for Research on Cancer. Cancer Today. Non-Hodgkin Lymphoma. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/34-non-hodgkin-lymphoma-fact-sheet.pdf. Accessed April 2025.
      [8] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263. doi:10.3322/caac.21834.
      [9] Globocan 2022. International Agency for Research on Cancer. Cancer Today. Bladder. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/30-bladder-fact-sheet.pdf. Accessed April 2025.
      [10] Awada H, Ali A H, Zeineddine M A, et al. The status of bladder cancer research worldwide, a bibliometric review and recommendations. Arab Journal of Urology. 2022; 21(1): 1–9. https://doi.org/10.1080/2090598X.2022.2152237. Accessed April 2025.
      [11] Globocan 2022. International Agency for Research on Cancer. Cancer Today. Prostate. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/27-prostate-fact-sheet.pdf. Accessed April 2025.
      [12] Globocan 2022. International Agency for Research on Cancer. Cancer Today. Europe. Available at: https://gco.iarc.who.int/media/globocan/factsheets/populations/908-europe-fact-sheet.pdf. Accessed April 2025.
      [13] World Health Organisation. Lung Cancer. 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/lung-cancer#:~:text=Key%20facts,approximately%2085%25%20of%20all%20cases. Accessed December 2024.
      [14] National Cancer Institute. B-cell lymphoma. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/b-cell-lymphoma. Accsessed December 2024.
      [15] European Cancer Patient Coalition White Paper on Bladder Cancer. 2020. Available at: https://ecpc.org/wp-content/uploads/2019/08/ECPC-White-Paper-Bladder-Cancer-EN-1.pdf. Accessed December 2024.
      [16] Montazeri, K and Bellmunt, J. Erdafitinib for the treatment of metastatic bladder cancer. Expert Review of Clinical Pharmacology. 2020;13(1):1-6. Accessed December 2024.

      CP-512006
      May 2025